a public good project by the
Synthesis
Company
of California

© 2026

Boris Hadaschik | doi.page

0 works0 citations0 h-index

Boris Hadaschik

Essen University Hospital(DE)University of Duisburg-Essen(DE)

Publications by Year

Research Areas

Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Bladder and Urothelial Cancer Treatments, Cancer, Lipids, and Metabolism

Most-Cited Works

→ MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis(2018)2,923 cited
→ Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer(2018)1,305 cited
→ The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer(2014)971 cited
→ PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions(2012)919 cited
→ Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer(2013)919 cited
→ Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT(2017)586 cited

→ F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients(2016)

581 cited

→ Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging–Ultrasound Fusion Targeted Biopsy: A Systematic Review(2014)450 cited

→ Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group(2013)447 cited

→ Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy(2014)352 cited